Trial Profile

A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE FL-2)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epcoritamab (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Obinutuzumab; Prednisone; Vincristine
Indications Follicular lymphoma
Focus Registrational; Therapeutic Use
Acronyms EPCOR FL-2
Sponsors Genmab

03 Nov 2025 According to Genmab media release, data from the study will be presented at the 67th Annual Meeting and Exposition of the American Society of Hematology (ASH), in Orlando, Florida, and online, December 6-9.
30 Apr 2025 Planned number of patients changed from 1080 to 1095.
03 Dec 2024 Planned End Date changed from 18 May 2037 to 1 Nov 2037.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com